XOMA Royalty (XOMA) Cash & Current Investments (2010 - 2026)
XOMA Royalty (XOMA) reported Cash & Current Investments of $86.1 million for Q1 2026, down 7.07% on a YoY basis from $92.6 million in Q1 2025, and up 3.34% sequentially from $83.3 million in Q4 2025.
XOMA Royalty (XOMA) Cash & Current Investments (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 17 years of Cash & Current Investments data on file, last reported at $86.1 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Current Investments fell 7.07% year-over-year to $86.1 million; the trailing twelve-month figure through Mar 2026 stood at $86.1 million (down 7.07% YoY), and the FY2025 full-year result was $83.3 million, down 19.11% from the prior year.
- Cash & Current Investments rose to $86.1 million in Q1 2026, from $83.3 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $153.4 million in Q4 2023 to a low of $335000.0 in Q4 2022.
- A 5-year average of $75.3 million and a median of $83.7 million in 2022 frame the typical range for Cash & Current Investments.
- Across the five-year window, Cash & Current Investments slumped 99.65% in 2022 and soared 45705.97% in 2023, its largest moves.
- Tracing XOMA's Cash & Current Investments over 5 years: stood at $335000.0 in 2022, then soared by 45705.97% to $153.4 million in 2023, then tumbled by 32.89% to $103.0 million in 2024, then decreased by 19.11% to $83.3 million in 2025, then rose by 3.34% to $86.1 million in 2026.
- Business Quant data shows XOMA's Cash & Current Investments at $86.1 million in Q1 2026, $83.3 million in Q4 2025, and $108.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 86.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.09 Mn |
| Dec 31, 2025 | 83.31 Mn |
| Sep 17, 2025 | 108.00 Mn |
| Jun 30, 2025 | 7.07 Mn |
| Mar 31, 2025 | 92.65 Mn |
| Dec 31, 2024 | 102.98 Mn |
| Sep 30, 2024 | 4.80 Mn |
| Jun 30, 2024 | 144.60 Mn |
| Mar 31, 2024 | 136.40 Mn |
| Dec 31, 2023 | 153.45 Mn |
| Sep 30, 2023 | 33.69 Mn |
| Jun 30, 2023 | 31.77 Mn |
| Mar 31, 2023 | 44.61 Mn |
| Dec 31, 2022 | 335,000.00 |
| Sep 30, 2022 | 78.73 Mn |
| Jun 30, 2022 | 83.71 Mn |
| Mar 31, 2022 | 88.34 Mn |
| Dec 31, 2021 | 95.38 Mn |
| Sep 30, 2021 | 72.17 Mn |
| Jun 30, 2021 | 81.26 Mn |